Alector, Inc.
$2.71
▼
-4.74%
2026-04-21 05:13:00
www.alector.com
NMS: ALEC
Explore Alector, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$298.53 M
Current Price
$2.71
52W High / Low
$3.4 / $0.9
Stock P/E
—
Book Value
$0.28
Dividend Yield
—
ROCE
-69.73%
ROE
-1.82%
Face Value
—
EPS
$-1.39
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
103
Beta
0.58
Debt / Equity
118.22
Current Ratio
3.83
Quick Ratio
3.83
Forward P/E
-2.78
Price / Sales
12.85
Enterprise Value
$50.6 M
EV / EBITDA
-0.34
EV / Revenue
2.4
Rating
Hold
Target Price
$2.88
EPS Forecast (FY)
—
Pros
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Arrowhead Pharmaceuticals, Inc. | $71.64 | 46.54 | $10.05 B | — | 8.27% | 75.5% | $76.76 / $10.92 | $4.14 |
| 2. | Cytokinetics, Incorporated | $65.05 | — | $8.11 B | — | -50.1% | 197.47% | $70.98 / $29.31 | $-5.37 |
| 3. | Apollomics, Inc. | $13.53 | — | $15.34 M | — | -737.55% | -3.8% | $42.12 / $3.66 | $-3.99 |
| 4. | Corcept Therapeutics Incorporated | $46.34 | 49.18 | $4.9 B | — | 6.68% | 15.02% | $91 / $28.66 | $6.11 |
| 5. | CytomX Therapeutics, Inc. | $4.89 | — | $1.06 B | — | -21.31% | -35.25% | $8.21 / $0.61 | $0.58 |
| 6. | Creative Medical Technology Holdings, Inc. | $2.26 | — | $9.13 M | — | -81.64% | -86.47% | $6.25 / $1.5 | $2.03 |
| 7. | Aligos Therapeutics, Inc. | $6.51 | — | $41.33 M | — | -130.74% | -1.97% | $13.69 / $4.2 | $8.67 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | |
|---|---|---|---|---|---|
| Sales | 6.24 M | 3.26 M | 7.87 M | 3.67 M | 54.24 M |
| Operating Profit | -39.57 M | -37.61 M | -34.14 M | -44.7 M | -7.25 M |
| Net Profit | -37.27 M | -34.67 M | -30.52 M | -40.47 M | -2.07 M |
| EPS in Rs | -0.34 | -0.31 | -0.28 | -0.37 | -0.02 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 21.05 M | 100.56 M | 97.06 M | 133.62 M |
| Operating Profit | -156.01 M | -145 M | -151.74 M | -137.83 M |
| Net Profit | -142.93 M | -119.05 M | -130.39 M | -133.31 M |
| EPS in Rs | -1.3 | -1.08 | -1.18 | -1.21 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 293.24 M | 468.3 M | 621.83 M | 787.65 M |
| Total Liabilities | 262.59 M | 341.5 M | 487.67 M | 573.21 M |
| Equity | 30.65 M | 126.8 M | 134.16 M | 214.44 M |
| Current Assets | 266.45 M | 424.82 M | 565.81 M | 726.43 M |
| Current Liabilities | 69.5 M | 125.06 M | 177.95 M | 93.81 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -184.03 M | -229.91 M | -184.16 M | -20.33 M |
| Investing CF | 196.6 M | 107.13 M | 101.92 M | -159.01 M |
| Financing CF | 20.21 M | 81.54 M | 2.55 M | 4.51 M |
| Free CF | -184.07 M | -231.16 M | -186.54 M | -24.45 M |
| Capex | -0.04 M | -1.25 M | -2.38 M | -4.12 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue Growth % | -79.07% | 3.6% | -27.36% | — |
| Earnings Growth % | -20.06% | 8.7% | 2.19% | — |
| Profit Margin % | -679.16% | -118.39% | -134.34% | -99.77% |
| Operating Margin % | -741.3% | -144.19% | -156.33% | -103.16% |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | -695.4% | -135.4% | -147.22% | -96.82% |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.